Potential role of nonstatin cholesterol lowering agents

Laura Trapani, Marco Segatto, Paolo Ascenzi, Valentina Pallottini

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Although statins, 3β-hydroxy-3β-methylglutaryl coenzyme A reductase (HMGR) inhibitors, have revolutionized the management of cardiovascular diseases by lowering serum low density lipoproteins, many patients suffer from their side effects. Whether the statin side effects are related to their intrinsic toxicity or to the decrease of HMGR main isoprenoid end products, which are essential compounds for cell viability, is still debated. In addition to HMGR, the key and rate limiting step of cholesterol synthesis, many enzymes are involved in this multi-step pathway whose inhibition could be taken into account for a "nonstatin approach" in the management of hypercholesterolemia. In particular, due to their unique position downstream from HMGR, the inhibition of squalene synthase, farnesyl diphosphate farnesyltransferase (FDFT1), squalene epoxidase (SQLE), and oxidosqualene cyclase:lanosterol synthase (OSC) should decrease plasma levels of cholesterol without affecting ubiquinone, dolichol, and isoprenoid metabolism. Thus, although FDFT1, SQLE and OSC are little studied, they should be considered as perspective targets for the development of novel drugs against hypercholesterolemia. Here, structurefunction relationships of FDFT1, SQLE, and OSC are reviewed highlighting the advantages that the downstream inhibition of HMGR could provide when compared to the statin-based therapy.

Original languageEnglish
Pages (from-to)964-971
Number of pages8
JournalIUBMB Life
Volume63
Issue number11
DOIs
Publication statusPublished - Nov 2011

Fingerprint

Cholesterol
Coenzyme A
Oxidoreductases
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Farnesyl-Diphosphate Farnesyltransferase
Terpenes
Hypercholesterolemia
Dolichol
Ubiquinone
LDL Lipoproteins
Metabolism
Toxicity
lanosterol synthase
Cell Survival
Cardiovascular Diseases
Cells
Plasmas
Enzymes
Serum
Pharmaceutical Preparations

Keywords

  • 3-hydroxy 3-methylglutaryl coenzyme a reductase
  • Cholesterol
  • Hypercholesterolemia
  • Inhibition
  • Oxidosqualene cyclase
  • Squalene epoxidase
  • Squalene synthase

ASJC Scopus subject areas

  • Biochemistry
  • Cell Biology
  • Clinical Biochemistry
  • Molecular Biology
  • Genetics

Cite this

Trapani, L., Segatto, M., Ascenzi, P., & Pallottini, V. (2011). Potential role of nonstatin cholesterol lowering agents. IUBMB Life, 63(11), 964-971. https://doi.org/10.1002/iub.522

Potential role of nonstatin cholesterol lowering agents. / Trapani, Laura; Segatto, Marco; Ascenzi, Paolo; Pallottini, Valentina.

In: IUBMB Life, Vol. 63, No. 11, 11.2011, p. 964-971.

Research output: Contribution to journalArticle

Trapani, L, Segatto, M, Ascenzi, P & Pallottini, V 2011, 'Potential role of nonstatin cholesterol lowering agents', IUBMB Life, vol. 63, no. 11, pp. 964-971. https://doi.org/10.1002/iub.522
Trapani L, Segatto M, Ascenzi P, Pallottini V. Potential role of nonstatin cholesterol lowering agents. IUBMB Life. 2011 Nov;63(11):964-971. https://doi.org/10.1002/iub.522
Trapani, Laura ; Segatto, Marco ; Ascenzi, Paolo ; Pallottini, Valentina. / Potential role of nonstatin cholesterol lowering agents. In: IUBMB Life. 2011 ; Vol. 63, No. 11. pp. 964-971.
@article{149c2e1b58724d6f9630be8c8697d535,
title = "Potential role of nonstatin cholesterol lowering agents",
abstract = "Although statins, 3β-hydroxy-3β-methylglutaryl coenzyme A reductase (HMGR) inhibitors, have revolutionized the management of cardiovascular diseases by lowering serum low density lipoproteins, many patients suffer from their side effects. Whether the statin side effects are related to their intrinsic toxicity or to the decrease of HMGR main isoprenoid end products, which are essential compounds for cell viability, is still debated. In addition to HMGR, the key and rate limiting step of cholesterol synthesis, many enzymes are involved in this multi-step pathway whose inhibition could be taken into account for a {"}nonstatin approach{"} in the management of hypercholesterolemia. In particular, due to their unique position downstream from HMGR, the inhibition of squalene synthase, farnesyl diphosphate farnesyltransferase (FDFT1), squalene epoxidase (SQLE), and oxidosqualene cyclase:lanosterol synthase (OSC) should decrease plasma levels of cholesterol without affecting ubiquinone, dolichol, and isoprenoid metabolism. Thus, although FDFT1, SQLE and OSC are little studied, they should be considered as perspective targets for the development of novel drugs against hypercholesterolemia. Here, structurefunction relationships of FDFT1, SQLE, and OSC are reviewed highlighting the advantages that the downstream inhibition of HMGR could provide when compared to the statin-based therapy.",
keywords = "3-hydroxy 3-methylglutaryl coenzyme a reductase, Cholesterol, Hypercholesterolemia, Inhibition, Oxidosqualene cyclase, Squalene epoxidase, Squalene synthase",
author = "Laura Trapani and Marco Segatto and Paolo Ascenzi and Valentina Pallottini",
year = "2011",
month = "11",
doi = "10.1002/iub.522",
language = "English",
volume = "63",
pages = "964--971",
journal = "IUBMB Life",
issn = "1521-6543",
publisher = "Wiley-Blackwell",
number = "11",

}

TY - JOUR

T1 - Potential role of nonstatin cholesterol lowering agents

AU - Trapani, Laura

AU - Segatto, Marco

AU - Ascenzi, Paolo

AU - Pallottini, Valentina

PY - 2011/11

Y1 - 2011/11

N2 - Although statins, 3β-hydroxy-3β-methylglutaryl coenzyme A reductase (HMGR) inhibitors, have revolutionized the management of cardiovascular diseases by lowering serum low density lipoproteins, many patients suffer from their side effects. Whether the statin side effects are related to their intrinsic toxicity or to the decrease of HMGR main isoprenoid end products, which are essential compounds for cell viability, is still debated. In addition to HMGR, the key and rate limiting step of cholesterol synthesis, many enzymes are involved in this multi-step pathway whose inhibition could be taken into account for a "nonstatin approach" in the management of hypercholesterolemia. In particular, due to their unique position downstream from HMGR, the inhibition of squalene synthase, farnesyl diphosphate farnesyltransferase (FDFT1), squalene epoxidase (SQLE), and oxidosqualene cyclase:lanosterol synthase (OSC) should decrease plasma levels of cholesterol without affecting ubiquinone, dolichol, and isoprenoid metabolism. Thus, although FDFT1, SQLE and OSC are little studied, they should be considered as perspective targets for the development of novel drugs against hypercholesterolemia. Here, structurefunction relationships of FDFT1, SQLE, and OSC are reviewed highlighting the advantages that the downstream inhibition of HMGR could provide when compared to the statin-based therapy.

AB - Although statins, 3β-hydroxy-3β-methylglutaryl coenzyme A reductase (HMGR) inhibitors, have revolutionized the management of cardiovascular diseases by lowering serum low density lipoproteins, many patients suffer from their side effects. Whether the statin side effects are related to their intrinsic toxicity or to the decrease of HMGR main isoprenoid end products, which are essential compounds for cell viability, is still debated. In addition to HMGR, the key and rate limiting step of cholesterol synthesis, many enzymes are involved in this multi-step pathway whose inhibition could be taken into account for a "nonstatin approach" in the management of hypercholesterolemia. In particular, due to their unique position downstream from HMGR, the inhibition of squalene synthase, farnesyl diphosphate farnesyltransferase (FDFT1), squalene epoxidase (SQLE), and oxidosqualene cyclase:lanosterol synthase (OSC) should decrease plasma levels of cholesterol without affecting ubiquinone, dolichol, and isoprenoid metabolism. Thus, although FDFT1, SQLE and OSC are little studied, they should be considered as perspective targets for the development of novel drugs against hypercholesterolemia. Here, structurefunction relationships of FDFT1, SQLE, and OSC are reviewed highlighting the advantages that the downstream inhibition of HMGR could provide when compared to the statin-based therapy.

KW - 3-hydroxy 3-methylglutaryl coenzyme a reductase

KW - Cholesterol

KW - Hypercholesterolemia

KW - Inhibition

KW - Oxidosqualene cyclase

KW - Squalene epoxidase

KW - Squalene synthase

UR - http://www.scopus.com/inward/record.url?scp=84055199986&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84055199986&partnerID=8YFLogxK

U2 - 10.1002/iub.522

DO - 10.1002/iub.522

M3 - Article

C2 - 21990243

AN - SCOPUS:84055199986

VL - 63

SP - 964

EP - 971

JO - IUBMB Life

JF - IUBMB Life

SN - 1521-6543

IS - 11

ER -